These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 20547308)
1. Histopathological classification of hepatocellular carcinoma. Roncalli M; Park YN; Di Tommaso L Dig Liver Dis; 2010 Jul; 42 Suppl 3():S228-34. PubMed ID: 20547308 [TBL] [Abstract][Full Text] [Related]
2. Liver cancer stem cells: implications for a new therapeutic target. Lee TK; Castilho A; Ma S; Ng IO Liver Int; 2009 Aug; 29(7):955-65. PubMed ID: 19490415 [TBL] [Abstract][Full Text] [Related]
3. Primary liver tumors: origin and target therapy. Papoulas M; Theocharis S Expert Opin Ther Targets; 2009 Aug; 13(8):957-65. PubMed ID: 19606929 [TBL] [Abstract][Full Text] [Related]
4. Liver cell dysplasia in liver cirrhosis and hepatocellular carcinoma. Szczepański W Pol J Pathol; 1997; 48(3):147-57. PubMed ID: 9401407 [TBL] [Abstract][Full Text] [Related]
5. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases. Yeh MM; Larson AM; Campbell JS; Fausto N; Rulyak SJ; Swanson PE Am J Surg Pathol; 2007 May; 31(5):681-9. PubMed ID: 17460450 [TBL] [Abstract][Full Text] [Related]
7. Origin of hepatocellular carcinoma: role of stem cells. Wu XZ; Chen D J Gastroenterol Hepatol; 2006 Jul; 21(7):1093-8. PubMed ID: 16824058 [TBL] [Abstract][Full Text] [Related]
8. Early hepatocellular carcinoma and dysplastic nodules. Kojiro M; Roskams T Semin Liver Dis; 2005; 25(2):133-42. PubMed ID: 15918142 [TBL] [Abstract][Full Text] [Related]
9. Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors. Amarapurkar AD; Rege JD; Joshi AS; Vaiphei K; Amarapurkar DN Indian J Pathol Microbiol; 2006 Jul; 49(3):341-4. PubMed ID: 17001880 [TBL] [Abstract][Full Text] [Related]
10. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis]. Tátrai P Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466 [TBL] [Abstract][Full Text] [Related]
11. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Roncalli M; Bianchi P; Bruni B; Laghi L; Destro A; Di Gioia S; Gennari L; Tommasini M; Malesci A; Coggi G Hepatology; 2002 Aug; 36(2):427-32. PubMed ID: 12143052 [TBL] [Abstract][Full Text] [Related]
12. Flow cytometric DNA analysis of cirrhotic liver cells in patients with hepatocellular carcinoma can provide a new prognostic factor. Ruà S; Comino A; Fruttero A; Torchio P; Bouzari H; Taraglio S; Torchio B; Capussotti L Cancer; 1996 Sep; 78(6):1195-202. PubMed ID: 8826940 [TBL] [Abstract][Full Text] [Related]
14. [The diagnostic approach to hepatocellular carcinoma]. Schacherer D; Schoelmerich J; Zuber-Jerger I Z Gastroenterol; 2007 Oct; 45(10):1067-74. PubMed ID: 17924305 [TBL] [Abstract][Full Text] [Related]
15. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Roskams T Oncogene; 2006 Jun; 25(27):3818-22. PubMed ID: 16799623 [TBL] [Abstract][Full Text] [Related]
16. Natural history of hepatocellular carcinoma as viewed by the pathologist. Callea F Appl Pathol; 1988; 6(2):105-16. PubMed ID: 2839213 [TBL] [Abstract][Full Text] [Related]
17. [Clinicopathologic features and diagnosis of mixed type hepatocellular carcinoma]. Lu J; Lin Z; Yuan S Zhonghua Zhong Liu Za Zhi; 1995 May; 17(3):208-11. PubMed ID: 7656828 [TBL] [Abstract][Full Text] [Related]